Immune modulatory effects of antibiotics

Current Opinion in Infectious Diseases

Volumn 9, Issue 3, 1996, Pages 165-169

  Stevens, Dennis L ^a  

^a Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMPHENICOL; PENICILLIN G; VIRULENCE FACTOR;

ANAPHYLAXIS; APLASTIC ANEMIA; BACTERICIDAL ACTIVITY; EUKARYOTIC CELL; IMMUNOMODULATION; INTRACELLULAR KILLING; PHAGOCYTOSIS; SEIZURE; SHORT SURVEY;

EID: 0030055371     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199606000-00007     Document Type: Short Survey

References (28)

1. Scheffer J, Knoller J, Cullmann W, Konig W: Effects of cefaclor, cefetamet and Ro40-6890 on inflammatory responses of human granulocytes. J Antimicrob Chemother 1992, 30:57-66.
2. Gemmell CG, Peterson PK, Schmeling D, Mathews J, Quie PG: Antibiotic-induced modification of Bacteroides fragilis and its susceptibility to phagocytosis by human polymorphonuclear leukocytes. Eur J Clin Microbiol 1983, 2:327-334.
3. Milatovic D, Braveny I, Verhoef J: Clindamycin enhances opsonization of Staphylococcus aureus. Antimicrob Agents Chemother 1983, 24:413-417.
4. Gemmell CG, Peterson PK, Schmeling D, Kim Y, Mathews J, Wannamaker L, Quie PG: Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981, 67:1249-1256.
5. Gemmell CG, O'Dowd A: Regulation of protein A biosynthesis in Staphylococcus aureus by certain antibiotics: its effect on phagocytosis by leukocytes. J Antimicrob Chemother 1983, 12:587-597.
6. Lam C, Georgopoulos A, Laber G, Schutze E: Therapeutic relevance of penicillin-induced hypersensitivity of Staphylococcus aureus to killing by polymorphonuclear leukocytes. Antimicrob Agents Chemother 1984, 26:149-154.
7. Labro MT: Cefodizime as a biological response modifier: a review of its in-vivo, ex-vivo, and in-vitro immunomodulatory properties. J Antimicrob Chemother 1990, 26:37-47.
8. Pruul H, Wetherall BL, McDonald PJ: Enhanced susceptibility of Escherichia coli to intracellular killing by human polymorphonuclear leukocytes after in-vitro incubation with chloramphenicol. Antimicrob Agents Chemother 1981, 19:945-951.
9. Home D, Tomasz A: Hypersusceptibility of penicillin-treated group B streptococci to bactericidal activity of human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1981, 19:745-753.
10. Cuffini AM, Tullio V, Allocco A, Paizis G, DeLeo C, Carlone NA: Effect of rufloxacin upon non-specific immune defences: in-vitro, ex-vivo, and in-vivo results. J Antimicrob Chemother 1994, 34:545-553. This paper describes the enhancement of microbicidal activity of neutrophils by rufloxacin. The authors demonstrated this augmentation of neutrophil killing of Klebsiella pneumoniae using both in-vitro and ex-vivo techniques. In addition, in a mouse model of Candida albicans sepsis, rufloxacin markedly improved survival from 5.5% in the placebo group to 87.5% in the treated group.
11. Rakita RM, Michel BR, Rosen H: Inactivation of Escherichia coli penicillin-binding proteins by human neutrophils. Infect Immun 1994, 62:162-165.
12. Ras GJ, Anderson R, Taylor GW, Savage JE, Van Niekerk E, Joone G, Koornhof HJ, Saunders J, Wilson R, Cole PJ: Clindamycin, erythromycin, and roxithromycin inhibit the proinflammatory interactions of Pseudomonas aeruginosa pigments with human neutrophils in vitro. Antimicrob Agents Chemother 1992, 36:1236-1240.
13. Shibl AM: Effect of antibiotics on production of enzymes and toxins by microorganisms. Rev Infect Dis 1983, 5:865-875.
14. Stevens DL, Maier KA, Mitten JE: Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987, 31:213-218.
15. Arbo A, Mancilla C, Alpenche C, Santos JI: In-vitro and in-vivo effects of subinhibitory concentrations of clindamycin on experimental Klebsiella pneumoniae sepsis. Chemotherapy 1990, 36:337-344.
16. Wenisch C, Parschalk B, Hasenhundl M, Wiesinger E, Graninger W: Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections. Antimicrob Agents Chemother 1995, 39:672-676. These authors demonstrated that neutrophils from patients with infection demonstrated marked increases in the phagocytosis of fluorescein-labelled bacteria after they were treated with either cefodizime or ceftriaxone. These studies also demonstrated that post-treatment neutrophils generated higher quantities of reactive oxygen intermediates.
17. DeRemee RA, McDonald TJ, Weiland LH: Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985, 60:27-32.
18. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA: Minocycline in rheumatoid arthritis. A 48-week, double blind, placebo controlled trial. Ann Intern Med 1995, 122:81-89.
19. Hauser WE, Remington JS: Effect of antibiotics on the immune response. Am J Med 1982, 72:711-716.
20. Prins JM, Kuijper EJ, Mevissen MLCM, Speelman P, VanDeventer SJH: Release of tumor necrosis factor alpha and interleukin-6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995, 63:2236-2242. Log phase E. coli were incubated with concentrations of ceftazadime, ciprofloxacin, gentamicin, or imipenem in whole blood preparations. Lower quantities of cytokines were produced in preparations containing gentamicin or imipenem than in those containing the other two agents. The mechanism was probably related to greater quantities of LPS liberated in E. coli incubated with ceftazadime. Gentamicin may have released less LPS and the authors also suggest that binding of LPS by gentamicin may have further reduced the bioavailability of LPS.
21. Artenstein AW, Cross AS: Inhibition of endotoxin reactivity by aminoglycosides. J Antimicrob Chemother 1989, 24:826-828.
22. Foca A, Matera G, Berlinghieri MC: Inhibition of endotoxin-induced interleukin 8 release by teicoplanin in human whole blood. Eur J Clin Microbiol Infect Dis 1993, 12:940-944.
23. Stevens DL, Bryant AE, Yan S: Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 1994, 4:297-301.
24. Parsonnet J, Modern PA, Giacobbe K: Effect of subinhibitory concentrations of antibiotics on production of toxic shock syndrome toxin-1 (TSST-1) [Abstract]. 32nd Annual Meeting of the Infectious Disease Society of America 1994. Orlando, Florida: Infectious Diseases Society of America; 1994.
25. Stevens DL, Bryant AE, Hackett SP: Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995, 20(suppl 2):S154-S157. Clindamycin suppressed TNF-α production by human peripheral blood mononuclear cells stimulated by LPS by approximately 40%. This may partly explain the greater efficacy of clindamycin compared with penicillin in the treatment of fulminant group A streptococcal infections such as necrotizing fasciitis and streptococcal toxic shock syndrome.
26. Kloppenburg M, Breedveld FC, Miltenburg AM, Dijkmans BA: Antibiotics as disease modifiers in arthritis. Clin Exp Rheumatol 1993, (Suppl 8)11:S113-S115.
27. Tamaoki J, Tagaya E, Yamawaki I, Sakai N, Nagai A, Konno K: Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med 1995, 151:1582-1588. Erythromycin administration for 1 week before inhalation challenge with LPS from E. coli protected rats from lung injury, microvascular leakage and neutrophil recruitment into the trachea.
28. Witkin SS, Jeremias J, Toth M, Ledger WJ: Antibiotic-induced monocyte inhibition: possible role in treating chlamydial infection. Infect Dis Clin Practice 1993, 2:182-185.